Multiple Myeloma Clinical Trial
Official title:
A Early Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory multiple myeloma or plasma cell leukemia.
Status | Recruiting |
Enrollment | 18 |
Est. completion date | September 30, 2027 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria:Subjects must meet all of the following criteria to be enrolled: - Subjects volunteer to participate in clinical trials, understand and sign the informed consent document, be willing to complete all the trial procedures; - 18 years and older, Male and female; - Expected survival > 12 weeks; - Documented evidence of multiple myeloma at diagnosis as defined by IMWG updated criteria (2014), or plasma cell leukemia at diagnosis as defined by Diagnosis and therapeutic criteria of hematologic disease (4th edition); - One of the following indicators is satisfied: 1. Serum M protein: IgG M protein =5 g/L; or IgA M protein =5 g/L; or IgD M protein and IgD >ULN; 2. Urine M protein =200 mg/24h; 3. Affected serum free light chain =100 mg/L and Serum free light chain ratio is abnormal; 4. Clonal bone marrow plasma cells =10 % for non-secretory myeloma; - Patients with relapsed/refractory multiple myeloma or plasma cell leukemia, satisfying: 1. Patients have received at least 3 prior MM or PCL treatment regimens containing at least one proteasome inhibitor and one immunomodulatory; 2. Progress is documented within 60 days of the most recent anti-tumor treatment, or efficacy assessment does not reach minimal response(MR) or above; - Liver, kidney and cardiopulmonary functions meet the following requirements: 1. Creatinine clearance rate (estimated by CockcroftGault formula) =30mL/min; 2. Left ventricular ejection fraction > 50%; 3. Baseline peripheral oxygen saturation > 95%; 4. Total bilirubin= 2×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5×ULN; - Blood routine examination satisfying hemoglobin=60 g/L, neutrophils= 1.0×10^9/L, and platelets=30×10^9/L, can complete this trial according to the judgement of investigators. Exclusion Criteria:Any one of the following conditions cannot be selected as a subject: - Accompanied by other uncontrolled malignancies; - Subjects with positive Hepatitis B surface antigen(HBsAg) or Hepatitis B core antibody (HBcAb) and hepatitis B virus (HBV) DNA titers higher than the lower limit of the normal range of the investigative site; Hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; Human Immunodeficiency Viral (HIV) antibody positive; syphilis primary screening antibody positive; - Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification = III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease; - Subjects who are considered unsuitable to participate in this trial by the investigator. - Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion; - Received CAR-NK treatment or other gene therapies before enrollment; - Subjects who have a disease that affects the signing of written informed consent or who are unable to comply with research procedures; or who are unwilling or unable to comply with research requirements; - Subjects who have had severe immediate hypersensitivity reactions to any drugs used in this research; - Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment; - In the past two years, the terminal organ was damaged due to autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), or the systemic use of immunosuppressive or other systemic disease control drugs was required; - Patients with symptoms of central nervous system. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Changzheng Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Hrain Biotechnology Co., Ltd. | Shanghai Changzheng Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limited toxicity (DLT) | Safety Indicators | 28 days post infusion | |
Secondary | Pharmacokinetics parameters - the highest concentration of human BCMA targeted CAR-NK cells amplified in peripheral blood and bone marrow after infusion | Effectiveness Metrics | 2 years post infusion | |
Secondary | Pharmacokinetics parameters - the time to reach the highest concentration of human BCMA targeted CAR-NK cells amplified in peripheral blood and bone marrow after infusion | Effectiveness Metrics | 2 years post infusion | |
Secondary | Pharmacokinetics parameters - the 28-day area under the curve of human BCMA targeted CAR-NK cells amplified in peripheral blood and bone marrow after infusion | Effectiveness Metrics | 2 years post infusion | |
Secondary | Pharmacodynamics characteristics - the detection values of CRP, IL-6, IL-15, Granzyme B cytokines in peripheral blood | Effectiveness Metrics | 2 years post infusion | |
Secondary | Pharmacodynamics characteristics - the detection values of monoclonal plasma cell in bone marrow | Effectiveness Metrics | 2 years post infusion | |
Secondary | Overall response rate (ORR, include PR, VGPR, CR and sCR) after administration | Effectiveness Metrics | 3 months post infusion | |
Secondary | Percentage of subjects with negative minimal residual disease (MRD) | Effectiveness Metrics | 2 years post infusion | |
Secondary | Duration of subjects with negative minimal residual disease (MRD) | Effectiveness Metrics | 2 years post infusion | |
Secondary | Number of subjects with adverse events | Safety Metrics | 2 years post infusion | |
Secondary | Change from baseline in perform status as measured by Easten Cooperative Oncology Group (ECOG) score | 2 years post infusion | Safety Metrics | |
Secondary | The occurrence rate of adverse events grade=3 assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. | Safety Metrics | 2 years post infusion | |
Secondary | Change in body weight over time after infusion | Safety Metrics | 2 years post infusion | |
Secondary | Duration of remission (DOR) after administration | Effectiveness Metrics | 2 years post infusion | |
Secondary | Overall Survival (OS) after administration | Effectiveness Metrics | 2 years post infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |